The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1491
Seebri Neohaler and Utibron Neohaler for COPD
The full article is available to subscribers Subscriber Login   

The FDA has approved two new inhalers for long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). Seebri Neohaler (Novartis) contains the long-acting anticholinergic glycopyrrolate. Utibron Neohaler (Novartis) contains both glycopyrrolate and the long-acting beta2-adrenergic agonist (LABA) indacaterol. Glycopyrrolate/indacaterol is the third fixed-dose combination of a long-acting anticholinergic and a LABA to become available in the US; umeclidinium/vilanterol (Anoro Ellipta)1 and tiotropium/olodaterol (Stiolto Respimat)2 were approved earlier.

GLYCOPYRROLATE — Glycopyrrolate has been available for many years in a parenteral formulation for multiple indications. An oral formulation is available for reduction of chronic severe drooling in children with certain ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Seebri Neohaler and Utibron Neohaler for COPD
Article code: 1491a
 Electronic, downloadable article - $25